Vertex Pharmaceuticals Inc. (VRTX) News

Vertex Pharmaceuticals Inc. (VRTX): $229.02

0.41 (+0.18%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add VRTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 461

in industry

Filter VRTX News Items

VRTX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

VRTX News Highlights

  • For VRTX, its 30 day story count is now at 62.
  • Over the past 27 days, VRTX's stories per day has been in a clear downtrend, falling by about 0.52 per day.
  • CF, DRUG and EC are the most mentioned tickers in articles about VRTX.

Latest VRTX News From Around the Web

Below are the latest news stories about Vertex Pharmaceuticals Inc that investors may wish to consider to help them evaluate VRTX as an investment opportunity.

Enterprise Trust & Investment Co Buys Vanguard Materials ETF, Vertex Pharmaceuticals Inc, ...

Investment company Enterprise Trust & Investment Co (Current Portfolio) buys Vanguard Materials ETF, Vertex Pharmaceuticals Inc, Amgen Inc, Meta Platforms Inc, 3M Co, sells Eli Lilly and Co, McDonald's Corp, Sylvamo Corp, Fidelity High Yield Factor ETF, Vanguard Emerging Markets Government Bond ETF during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Enterprise Trust & Investment Co.

Yahoo | January 18, 2022

Top Analyst Reports for Bank of America, Broadcom & Royal Dutch Shell

Today's Research Daily features new research reports on 16 major stocks, including Bank of America Corporation (BAC), Broadcom Inc. (AVGO), and Royal Dutch Shell plc (RDS.A).

Yahoo | January 18, 2022

Vertex to Announce Fourth Quarter 2021 Financial Results on January 26

BOSTON --, January 18, 2022--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2021 financial results on Wednesday, January 26, 2022 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (866) 501-1537 (U.S.) or +1 (720) 545-0001 (International).

Yahoo | January 18, 2022

Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 49%?

Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Vertex Pharmaceuticals...

Yahoo | January 17, 2022

17 Capital Partners, Llc Buys Crown Castle International Corp, Constellation Brands Inc, SPDR ...

Investment company 17 Capital Partners, Llc (Current Portfolio) buys Crown Castle International Corp, Constellation Brands Inc, SPDR Portfolio S&P 500 Growth ETF, The Trade Desk Inc, Tyler Technologies Inc, sells Novartis AG, Zendesk Inc, Chegg Inc, Wells Fargo, Twitter Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, 17 Capital Partners, Llc.

Yahoo | January 14, 2022

4 Biotech Acquisitions We'd Like to See in 2022

Are some major acquisitions on the way in the biopharmaceutical industry this year? That remains to be seen. But there are some deals that Motley Fool contributors Brian Orelli and Keith Speights hope will happen.

Yahoo | January 14, 2022

Vaughan Nelson Investment Management, L.p. ...

Houston, TX, based Investment company Vaughan Nelson Investment Management, L.p. (Current Portfolio) buys Berkshire Hathaway Inc, Vertex Pharmaceuticals Inc, Ballys Corp, Beacon Roofing Supply Inc, Performance Food Group Co, sells Mastercard Inc, Moderna Inc, NVIDIA Corp, Meta Platforms Inc, Saia Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Vaughan Nelson Investment Management, L.p..

Yahoo | January 13, 2022

Vertex Pharmaceuticals (VRTX) Presents At 40th Annual J.P. Morgan Virtual Healthcare Conference

No summary available.

Seeking Alpha | January 12, 2022

Vertex (VRTX) Kaftrio Gets Europe Nod for CF in Children

The European Commission approves Vertex's (VRTX) triple combination therapy, Kaftrio, in combination with Kalydeco for treating cystic fibrosis in children aged between six and 11 years.

Yahoo | January 12, 2022

EC approves Vertex''s Kaftrio + ivacaftor for cystic fibrosis in children aged 6 to 11 years

Vertex Pharmaceuticals (VRTX) announces that the European Commission ((EC)) has granted approval for the label extension of KAFTRIO (ivacaftor/tezacaftor/elexacaftor) in a

Seeking Alpha | January 11, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.704 seconds.